24 May 2013
Keywords: bayer/j, xarelto, drive, anticoagulant, market, entries, oral
Article | 22 October 2007
Market entries of oral agents that do not require dose- adjustment or monitoring, particularly the entry of Bayer/Johnson & Johnson's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 October 2007
© 2013 thepharmaletter.com